Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.

Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.

Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.

An embodiment of a CBD or other cannabinoid or terpene or lipid-soluble Nano-Emulsion material and the process comprises a formulation comprising at least a lecithin or mixed lecithin, one or more carrier oils, and a Vitamin E TPGS from a sunflower version and a soy version or Polysorbate 80, 60 or 65. Among either version, the versions may further comprise mixed tocopherols and still further comprise at least one of; an LCT oil, an olive oil, and coconut oil. Any one of the versions may further comprise at least one of; sodium benzoate, potassium sorbate, and sorbic acid, and even yet further comprise purified water. Some embodiments may comprise a Vitamin E acetate or beeswax.

An embodiment of a CBD or other cannabinoid or terpene or lipid-soluble Nano-Emulsion material and the process comprises a formulation comprising at least a lecithin or mixed lecithin, one or more carrier oils, and a Vitamin E TPGS from a sunflower version and a soy version or Polysorbate 80, 60 or 65. Among either version, the versions may further comprise mixed tocopherols and still further comprise at least one of; an LCT oil, an olive oil, and coconut oil. Any one of the versions may further comprise at least one of; sodium benzoate, potassium sorbate, and sorbic acid, and even yet further comprise purified water. Some embodiments may comprise a Vitamin E acetate or beeswax.

Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.

Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.